Botox for upper-lip wrinkles: what the perioral evidence supports

BOTOX Cosmetic has no FDA-approved indication for vertical wrinkles around the upper lip. Clinicians may consider an approved drug for an off-label use, but the perioral evidence is narrower than the label evidence for approved sites: a 60-woman study found improvement in movement-related lines in two active-dose groups, without a placebo or untreated group. A useful consultation asks whether the target is a moving line and how any change in mouth movement would be assessed.¹²⁴

The question is about line severity near the lip, rather than making the lip look more everted. The lip-flip comparison owns that latter goal. It is also a different record from the upper-perioral filler guide, which examines exact filler approvals and trials. Calling every one of these services “lip Botox” hides the endpoint a person is actually buying.

What the named product label does—and does not—approve

The current BOTOX Cosmetic label lists aesthetic uses for glabellar lines, lateral canthal lines, forehead lines, and platysma bands. It does not list vertical upper-lip or perioral wrinkles. A product may be FDA-approved while a proposed location or purpose is off-label; FDA has not thereby approved every use of that product. The distinction belongs in the first consultation sentence, not in a footnote after a before-and-after image.¹⁴

Ask for the exact product name. The BOTOX Cosmetic label says its potency units cannot be converted into units of another botulinum-toxin preparation. A menu that quotes “units” without naming the product cannot be checked against the named product record. The label also carries a boxed warning about possible spread of toxin effect, including serious swallowing or breathing problems. That warning is a safety boundary; it is not a claim that the small perioral study measured the frequency of such events.¹

The regulatory distinction does not decide whether an individual should have a procedure. It tells a reader which evidence to ask a clinician to use. If a practice says “FDA-approved Botox for smoker’s lines,” the accurate question is whether it means an approved product used off-label or an approved indication for those lines. The current label supports the first description, not the second.¹⁴

Read the perioral study as an active-dose experiment

The most directly relevant study enrolled 60 women with hyperdynamic perioral lines. Researchers randomized participants between two active amounts of onabotulinumtoxinA and followed line-severity and lip-satisfaction measures at several visits through 20 weeks. Investigator-assessed line severity improved from baseline in both groups over different follow-up periods. Adverse events were dose-dependent. The study offers a concrete signal that movement-related perioral lines can change after treatment, in the selected people and observation window studied.²

It does not compare toxin with no treatment or placebo. Improvement from baseline can reflect treatment, but without an untreated comparison in this trial, the study cannot isolate every contribution of expectation, measurement variation, or other change. Nor does an active-dose comparison license an online article to specify an injection amount for an individual. The route, site, product, oral function, and treatment goal need an examining clinician’s judgment. The result also should not be described as a permanent fix: the study observed people for a finite period and assessed a particular line pattern.²

The study’s endpoint was hyperdynamic lines: those accentuated by lip movement. Deep lines visible without movement may include skin-surface and structural components that a movement-focused experiment did not isolate. A neutral photograph at rest and a short video during speech or a normal expression can help a clinician and patient agree on what they are comparing; neither image diagnoses the cause of a crease. Ask what would count as a useful result in the actual movement that bothers you, and what would remain unchanged.²

Keep the broader trial in its proper frame

A second randomized study assigned 90 women to onabotulinumtoxinA alone, a specific hyaluronic-acid filler alone, or both together for lower-face rejuvenation. Its outcomes included perioral appearance, lip fullness, oral commissures, and global ratings. The combined arm generally improved more across that study’s endpoints than either single arm. That finding cannot be shortened to “Botox plus filler is best for upper-lip wrinkles.” The trial mixed several lower-face goals, a specific filler formulation, and a selected population; it did not test every available product or isolate a single vertical-line outcome as a universal service ranking.³

For a reader who mainly wants added lip volume, that trial’s lip-fullness outcome may be more relevant than its line rating. For someone asking about a crease at rest, a study of moving lines and a lower-face combination trial answer different pieces of the question. A clinician can explain why either record is relevant to the observed concern without treating the results as interchangeable.

Mouth function belongs in the decision, not just the aftercare sheet

The original full report of the 60-woman study describes local adverse events, including lip weakness and effects on eating or lip mobility, within its selected treatment groups. Its sample is too small to give a reliable population rate for every such event. Still, the anatomy makes a practical consultation question clear: the muscles around the mouth support expression and everyday oral tasks. A proposed cosmetic change should be discussed alongside the person’s own speaking, drinking, eating, and work needs, not only a static photograph.²⁵

Ask the injector how oral movement is assessed before treatment, what change would be considered an unwanted functional effect, and how the practice handles a concern afterward. This is especially relevant for someone whose work relies on precise lip movement. The answer should be specific to the named product and planned goal, without promising that technique eliminates every risk. The product label’s boxed warning and contraindications should be reviewed separately from the small off-label efficacy studies.¹

If new difficulty breathing, swallowing, or speaking occurs after a botulinum-toxin injection, seek immediate medical attention; the BOTOX Cosmetic patient labeling treats these as potentially serious symptoms. A routine follow-up appointment is not a substitute for that response.¹

A useful consultation starts with one observable goal

Describe the exact line: upper lip or lower lip, visible at rest or mainly during expression, and the change that would matter to you. Ask the clinician to name the product, explain its FDA status for that site, identify the study endpoint that best resembles the concern, and discuss how mouth function will be checked. Request a written quote tied to the actual plan rather than assuming a familiar brand name specifies the number of visits or the total cost.

The filler evidence guide is useful if the proposed service places material in tissue for upper-perioral lines. The lip-flip guide is useful if the target is lip eversion. For a movement-related vertical line, compare Botox providers and ask for an explanation grounded in the exact product label, the limited perioral studies, and your functional priorities. That is a more testable decision than a generic promise to erase “smoker’s lines.”